#SITC18: Another underwhelming performance for STING damages Aduro’s already suffering share price
Aduro Biotech execs $ADRO made as much as they possibly could of the two partial responses researchers tracked among 40 heavily pre-treated cancer patients in an early-stage study of their STING therapy. But their defense at SITC wasn’t nearly enough to save the Berkeley, CA-based biotech from another beating at the hands of unhappy investors.
Merck set the stage at ESMO last month when researchers acknowledged that their rival STING therapy had no effect on tumors as a monotherapy, raising questions about the class and the drug at Aduro — which Novartis $NVS plunked down $200 million in cash to partner on.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
